Structure-activity analysis of peptidic Chlamydia HtrA inhibitors.

[1]  A. Gamble,et al.  Proteases and protease inhibitors in infectious diseases , 2018, Medicinal research reviews.

[2]  A. Gamble,et al.  Stereochemical basis for the anti-chlamydial activity of the phosphonate protease inhibitor JO146 , 2017 .

[3]  O. Forslund,et al.  Mycoplasma genitalium and Macrolide Resistance-associated Mutations in the Skåne Region of Southern Sweden 2015. , 2017, Acta dermato-venereologica.

[4]  Keith F. Tipton,et al.  Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs , 2017, Molecules.

[5]  G. Satpathy,et al.  Chlamydial eye infections: Current perspectives , 2017, Indian journal of ophthalmology.

[6]  P. Timms,et al.  Chlamydia Serine Protease Inhibitor, targeting HtrA, as a New Treatment for Koala Chlamydia infection , 2016, Scientific Reports.

[7]  Marleen Temmerman,et al.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting , 2015, PloS one.

[8]  J. Hocking,et al.  Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women , 2015, Clinical Microbiology Reviews.

[9]  P. Harrison,et al.  Ongoing unraveling of a continental fauna: Decline and extinction of Australian mammals since European settlement , 2015, Proceedings of the National Academy of Sciences.

[10]  M. Horn,et al.  Chlamydial metabolism revisited: interspecies metabolic variability and developmental stage-specific physiologic activities. , 2014, FEMS microbiology reviews.

[11]  M. Unemo,et al.  Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future , 2014, Clinical Microbiology Reviews.

[12]  M. Bogyo,et al.  Identification of a serine protease inhibitor which causes inclusion vacuole reduction and is lethal to Chlamydia trachomatis , 2013, Molecular microbiology.

[13]  I. Choroszy-Król,et al.  Characteristics of the Chlamydia trachomatis species - immunopathology and infections. , 2012, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[14]  M. Sieńczyk,et al.  Human neutrophil elastase phosphonic inhibitors with improved potency of action. , 2012, Journal of medicinal chemistry.

[15]  P. Horner.  Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy , 2012, Sexually Transmitted Infections.

[16]  P. Timms,et al.  The Active Site Residue V266 of Chlamydial HtrA Is Critical for Substrate Binding during both in vitro and in vivo Conditions , 2012, Journal of Molecular Microbiology and Biotechnology.

[17]  P. Timms,et al.  Unique Residues Involved in Activation of the Multitasking Protease/Chaperone HtrA from Chlamydia trachomatis , 2011, PloS one.

[18]  M. Horwitz,et al.  Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases , 2010, Pharmacological Reviews.

[19]  D. Rockey,et al.  Antibiotic resistance in Chlamydiae. , 2010, Future microbiology.

[20]  R. Huber,et al.  Determinants of structural and functional plasticity of a widely conserved protease chaperone complex , 2010, Nature Structural &Molecular Biology.

[21]  F. G. Njoroge,et al.  Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. , 2008, Accounts of chemical research.

[22]  Jonathan M. Harris,et al.  The temperature activated HtrA protease from pathogen Chlamydia trachomatis acts as both a chaperone and protease at 37 °C , 2007 .

[23]  A. Moulin,et al.  The epimerization of peptide aldehydes—a systematic study , 2006, Journal of peptide science : an official publication of the European Peptide Society.

[24]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[25]  L. Campbell,et al.  Chlamydia pneumoniae — an infectious risk factor for atherosclerosis? , 2004, Nature Reviews Microbiology.

[26]  A. Kaura,et al.  Design and synthesis of conformationally restricted eight-Membered ring diketones as potential serine protease inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[27]  C. Decicco,et al.  α-Ketoamides, α-ketoesters and α-diketones as HCV NS3 protease inhibitors , 2000 .

[28]  P. Timms,et al.  Epizootiology of Chlamydia infections in two free-range koala populations. , 1999, Veterinary microbiology.

[29]  P. Timms,et al.  Characterization of the koala biovar of Chlamydia pneumoniae at four gene loci--ompAVD4, ompB, 16S rRNA, groESL spacer region. , 1999, Systematic and applied microbiology.

[30]  K. Kramer,et al.  Rapid microplate assay for substrates and inhibitors of proteinase mixtures. , 1997, BioTechniques.

[31]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[32]  A. Tulinsky,et al.  Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group. , 1996, Journal of medicinal chemistry.

[33]  P. Edwards,et al.  Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency. , 1995, Journal of medicinal chemistry.

[34]  R. Dodd,et al.  A new efficient synthesis of ethyl β-carboline-3-carboxylate (β-CCE) and methyl 4-methyl-β-carboline-3-carboxylate (4-methyl-β-CCM) starting fr , 1994 .

[35]  A. Easton,et al.  Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. , 1993, The Journal of infectious diseases.

[36]  Edgar F. Meyer,et al.  Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl .alpha.-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole , 1992 .

[37]  A. Konradi,et al.  Intermolecular pinacol cross coupling of electronically similar aldehydes. An efficient and stereoselective synthesis of 1,2-diols employing a practical vanadium(II) reagent , 1989 .

[38]  W. Appel.  Chymotrypsin: molecular and catalytic properties. , 1986, Clinical biochemistry.

[39]  R. Huber,et al.  X‐ray crystal structure of the complex of human leukocyte elastase (PMN elastase) and the third domain of the turkey ovomucoid inhibitor. , 1986, The EMBO journal.